Why the study?
Does trimetazidine improve symptoms, cardiac function, and clinical outcomes in adults with chronic heart failure?
Does trimetazidine improve symptoms, cardiac function, and clinical outcomes in adults with chronic heart failure?
In a meta-analysis of 17 trials, trimetazidine was associated with significant improvements in left ventricular ejection fraction, NYHA class, and exercise duration, as well as substantial reductions in all-cause mortality and cardiovascular events in patients with heart failure.
No takes yet. Share an insight, caveat, or question.
Supports trimetazidine in chronic heart failure; confirms large mortality and event reductions across 17 trials.
Gao et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: